Nearly half of patients with colorectal cancer (CRC), the third leading cause of cancer deaths worldwide, are diagnosed in the late stages of the disease. Appropriate treatment is not applied in a timely manner and nearly 90% of the patients who experience metastasis ultimately die. Timely detection of CRC can increase the five-year survival rate of patients. Existing histopathological and molecular classifications are insufficient for prediction of metastasis, which limits approaches to treatment. Detection of reliable cancer-related biomarkers can improve early diagnosis, prognosis, and treatment response prediction and recurrence risk. Circulating tumor cells (CTCs) and exosomes in peripheral blood can be used in a liquid biopsy to assess the status of a tumor. Exosomes are abundant and available in all fluids of the body, have a high half-life and are released by most cells. Tumor-derived exosomes are released from primary tumors or CTCs with selective cargo that represents the overall tumor. The current systematic review highlights new trends and approaches in the detection of CRC biomarkers to determine tumor signatures using CTC and exosomes. When these are combined, they could be used to guide molecular pathology and can revolutionize detection tools. Relevant observational studies published until July 24, 2019 which evaluated the expression of tumor markers in CTCs and exosomes were searched in PubMed, Scopus, Embase, and ISI Web of Science databases. The extracted biomarkers were analyzed using String and EnrichR tools.
Introduction
Colorectal cancer (CRC) is the third highest cause of cancer deaths worldwide. 1, 2 The time of diagnosis directly influences the overall survival rate of patients. The five-year survival rates are estimated to decrease 12.5% after the occurrence of metastasis vs for localized cancer. Histological examination of tumor tissue is the gold standard for diagnosis, but is invasive, time-consuming, and nonrepeatable over time. There is a need for new methods that are simple, non-invasive, and inexpensive to provide clear clinical evidence and improve early detection or predict a response to treatment. 3, 4 Serum biomarkers such as carcinoembryonic antigens (CEAs) and carbohydrate antigen 19-9 (CA19-9) along with multi-target stool DNA tests represent the concrete implementation of non-invasive methods for CRC screening 5, 6 There is urgent need for more reliable molecular markers that demonstrate the heterogeneity of cancer cells during progression. The use of biological fluids as sources of nucleic acid-biomarkers for liquid biopsies in oncology has clinical promise 7, 8 Molecular characterization of cancer signatures also can provide relevant information for personalized treatment of tumors. 9, 10 Circulating tumor cells (CTCs) and exosomes are shed from a tumor mass and enter the bloodstream. They can provide a metastatic niche for the invasion and migration of a tumor, so detection of their markers is critical. 11 Ashworth et al, first identified CTCs as valuable indicators of cancer progression. 12 CTCs detach from the primary tumor, intravasate into the bloodstream, evade immune detection, survive and extravasate into the microvessels of target tissue to establish a micro-metastatic niche. 13 They have been identified in many cancers, including colon cancer. CTCs in the bloodstream may exist as single cells with a different EMT phenotypes or as clusters that bind to platelets or macrophages or are reactivated as stromal cells. 14, 15 The presence and number of CTCs before and during treatment are a strong independent predictor of shorter progression-free survival and overall survival of CRC patients. 16 In spite of their advantages, researchers believe that the most challenging obstacles related to research on CTCs are their extremely low numbers, short lifetimes, fragility, and their heterogeneity and plasticity. The investigation of specific and reliable markers for their detection or isolation is an undeniable issue. 17 Extracellular vesicles (EVs) generally include microvesicles (100-350 nm), apoptotic bodies (500-1000 nm), and exosomes (30-150 nm) . 18 Exosomes are nanovesicles with membrane-bound phospholipids which introduced and confirmed by Pan et al, 19 and are actively secreted by mammalian cells into body fluids such as urine, plasma, and saliva. Exosomal cargo includes lipids, proteins, DNA, and RNA (mRNA, miRNA, long non-coding RNA) that are selected according to their roles. Exosomes involved in many biological processes, especially intercellular communication, establish a premetastatic niche by carrying oncogenic elements that suppress host immune responses. 20 Exosomes are abundant, have high half-lives and are released by most cells. This is in contrast with CTCs, which are tumor specific, rare, fragile, have a short life and are difficult to isolate. It is possible to design a molecular marker common between the exosomes and CTCs for better understanding of the metastasis process. American Society of Clinical Oncology suggests circulating exosomes may provide an alternative platform for monitoring disease progression as opposed to CTCs. 21 Several ongoing studies have aimed at quantifying a stress protein or other biomarkers in the blood and urine for monitoring and early diagnosis of malignant solid tumors (https://clinicaltrials.gov). The current analytical review is the first to explore similar molecular mechanisms and pathways between CTCs and Exosomes. In this systematic review, all molecular mechanisms that can potentially apply to the diagnosis and prognosis of CRC using CTCs and exosomes are discussed.
Materials and methods

Search strategy for literature mining
Observational studies evaluating the expression of circulating CRC cells and exosomes markers from 1980 to July 24, 2019 were electronically searched for in the PubMed, Scopus, Embase, and ISI Web of Science databases. The search syntax was modified for each database in accordance with their rules, the Mesh terms and keywords as listed in detail in Table 1 .
The authors (S. Vafaei and F. Fattahi) searched and identified eligible studies and excluded all irrelevant articles after reviewing the publication titles and abstracts. Duplicate publications were excluded. Discrepancies were resolved between the two reviewers by consensus and by consulting the other authors. Next, the full text of the selected publications was retrieved and fully reviewed. This systematic review has been carried out in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. 22 
Publication inclusion criteria
The inclusion criteria for this systematic review followed the criteria of population, intervention, control, and outcomes. Observational studies (case-control) investigating CTC and exosomes mRNA and gene markers for the diagnosis and prognosis of CRC patient samples were included if they met the following criteria:
1. The article must be published in English and the full text must be available. 2. Studies included those on CRC patient blood samples and human blood for CTC, although tissue or cell lines for exosomes were done because exosomes research is rare and in its initial stages. 3. Expression of mRNA and gene markers in patient specimens or cell lines was detected by established molecular methods. ((neoplasm OR cancer OR tumor OR tumors OR carcinoma))) OR (TITLE-ABS-KEY ((colorectal AND neoplasms OR crc)))) AND (LIMIT-TO (DOCTYPE, "ar") OR LIMIT-TO (DOCTYPE, "ip")) AND (LIMIT-TO (EXACTKEYWORD, "Human")) AND (LIMIT-TO (LANGUAGE, "English")) AND (LIMIT-TO (SRCTYPE, "j"))
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PUBMED "mRNA" OR "RNA" OR "Transcriptome" OR "gene expression profiling")))) Filters: Humans; English OR "Transcriptome"[Mesh] OR "Gene Expression Profiling"[Mesh] OR "mRNA" OR "RNA" OR "Transcriptome" OR "gene expression profiling")))) AND ((("extracellular vesicles"[Mesh] OR "Cell-Derived Microparticles"[Mesh] OR "EV" OR "microvesicle" OR "extracellular vesicle" OR "Exosomes"[Mesh] OR Exosome))))) Filters: Humans; English In exosome studies, because of the limited data, we reviewed all articles on all markers that were introduced using the cell lines, tissue, or blood, even those only introduced through bioinformatics means without experimental confirmation.
Risk of bias (quality) assessment
The quality of each study was assessed using the Newcastle-Ottawa Scale (NOS), a well-known scale for assessing the quality and risk of bias in observational studies. 23 NOS gives a score between 0 (minimum) and 9 (maximum). Studies with a NOS score >6 were considered to be of high quality, making them possible for use as potential moderators in meta-regression analysis.
Statistical analysis
Because the studies included were not sufficiently similar in terms of study design, experimental techniques, and heterogeneity of genetic variants, a meta-analysis was not performed.
Bioinformatics approach to systematic search
Molecular pathology is a valuable tool in the development of a cancer signature. The initially extracted markers in this article were subjected to STRING (https://string-db.org/) for better understanding of the significantly related pathway and secondary data were enriched using the EnrichR (amp.pharm.mssm.edu/Enrichr/) web tool. The GO project provided ontologies to describe the attributes of the gene products in the non-overlapping domains of molecular biology. Molecular function describes activities (such as catalytic or binding activities) at the molecular level. Biological processes describe biological goals accomplished by one or more ordered assemblies of molecular functions. Cellular component describes the locations of subcellular structures and macromolecular complexes. 24 
Results
Literature
The initial search retrieved a total of 607 studies using the search strategy. After primary selection, 497 papers were 
Clinical applications of CTCs and exosomes in CRC as diagnostic markers CTCs
Antigen expression of circulating cells and their specific phenotypes affects the progression of cancer and patient survival; thus, the focus was on CTC molecular markers that could lead to the detection of CTC rather than isolation in blood samples. CTC detection methods included realtime polymerase chain reaction (RT-PCR), flow cytometry, fluorescence in situ hybridization, and immunocytochemistry. Isolation methods included Cellsearch, OncoQuick, Filration, magnetic-activated cell sorting, fluorescence-activated cell sorting, Adnatest Colon Cancer Select and Detect, CELLection electrophoresis assay, and microfluidic devices. When attempting to find more reliable markers for CTCs in CRC cases, 6 out of 39 articles described only CK20 mRNA as the target gene, which is not transcribed in normal hematopoietic cells. It has previously been reported through immunohistochemistry by Moll et al, [25] [26] [27] [28] [29] [30] and has been seen in control blood samples through sensitivity assay and sampling, 29 in addition to CK20, CA19-9, and CEA, which is used in clinics routinely for CRC detection, also has been introduced as a marker of CTC in CRC. Six of 39 studied examined CEA alone [31] [32] [33] [34] [35] [36] or in association with markers such as CK19, 37, 38 anti-epithelial cell adhesion molecule (EPCAM), [39] [40] [41] [42] [43] and transmission electron microscopy (TEM)-8. 44 Wong et al, used a sensitivity assay for the detection of CTCs and nodal metastases using CD44 splice variants as a tumor marker. 45 It has been proven that RT-PCR in combination with positive isolation of epithelial tumor cells (addition of Ber-EP4 immunomagnetic) and negative isolation of non-epithelial cells (CD45 immunomagnetic beads used to deplete leukocytes from MNC) could improve detection. 30, 36 Guanylyl-cyclase C (GCC) is another marker introduced to detect rare epithelial circulating metastatic cancer cells. [46] [47] [48] After 2004, researchers focused on multi-marker panels in literature or data mining as listed in Table 2 . [49] [50] [51] [52] [53] [54] [55] [56] Besides these, novel markers such as serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), SERPINB5, 57 epidermal growth factor receptor (EGFR), [58] [59] [60] epithelial cell transforming sequence 2 oncogene (ECT2) 61 FAM172A, 62 A3 receptor 63 have been examined as well as other markers, especially through bioinformatics analysis. 64 
Exosomes
Exosome isolation methods consisted of ultracentrifugation, commercial kits, and a combination of several methods based on their physical, chemical, immunological, and molecular markers. Characterization of exosomes was also achieved based on morphology, such as with scanning electron microscopy and TEM, based on size, such as with dynamic light-scattering and nanoparticle tracking assay or based on molecular profiling through conventional enzyme-linked immunosorbent assay, polymerase chainreaction, and Western blotting.
Exosomes carry molecular markers such as DNA, RNA, and proteins. Many reports indicate that exosomes contain miRNAs; [65] [66] [67] [68] moreover, blood EVs contain a substantial fraction of intact mRNAs [69] [70] [71] [72] and a large number of assembling spliced junctions-circRNAs 73 and long non-coding RNAs. 72, 74, 75 Exosomal proteins belong to the following functional groups: tetraspanins, including CD63 antigen (CD63), CD9 antigen (CD9), CD81 antigen (CD81), heat shock proteins (HSC70 and HSC90), and endosomal sorting complexes required for transport proteins such as Alix and TSG101, found in a wide range of exosomes. 76 The size of the extra vesicles varied and could influence gene expression. Larger vesicles (<100 nm) exhibited the greatest amount of EPCAM in extracted exosomes of HCT116 (CRC cell line) cells. 77 The level of glypican-1 was evaluated in exosomes of patients before and after surgical treatment. 78 KRTAP5-4 and MAGEA3 mRNA in the serum of patients could be used as diagnostic biomarkers to detect CRC. 79 Ct-OATP1B3 mRNA was present in EVs derived from HCT116, HT-29, and SW480 cells that were declared to be serum-based CRC biomarkers, 80 Huang et al, introduced UBC, H3F3A, HIST2H2AA3, AKT3, and HSPA1B as hub genes in bioinformatic analysis to serve as diagnostic markers and therapeutic targets of CRC in the future. 81 Table 3 shows all of these results.
Clinical applications of CTCs and exosomes in CRC as prognostic markers CTCs
Many researchers had discovered prognostic markers related to CRC as a beneficial tool for the detection of CTC. Five papers reported only CK20-positive as a prognostic marker. It caused significantly shorter survival in patients than the CK 20-negative marker. [82] [83] [84] [85] [86] However, some studies emphasized only on CEA as a marker (five articles) [87] [88] [89] [90] [91] and several studies also introduced both CK20 and CEA as prognostic markers. [92] [93] [94] [95] [96] In most articles, CK20 and/or CEA were accompanied by markers such as CK19, 97 110, 111 ProtM, 112 mucin 1 (MUC 1), 105 and mucin 2 (MUC 2), 99 and telomerase reverse transcriptase (hTERT). 101, 113, 114 Douard et al, showed that the expression of carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5; formerly CEA) 102, 115 and CEACAM7 (formerly CGM2) 115, 116 was more sensitive than use of a single marker in detecting CTCs, in contrast to the other studies, Bessa et al, showed that assessment of CTCs using RT-PCR CEA before surgery does not have prognostic value for CRC patients. 117 Some articles examined markers that had been investigated previously, such as EGFR, 107, [118] [119] [120] [121] Plastin3), 122, 123 anterior gradient-2, 102,124,125 leucine-rich repeat-containing-G-protein-coupled receptor 5, 102,109,126-128 double cortin-like kinase 1, 109,127 twist family bHLH transcription factor 1, 110,129 and aldehyde dehydrogenase 1 105, 129 as prognostic markers in CRC through CTC.
Gradilone et al, assessed CK19 (75%), CK20 (8%), and EGFR (25%) expression in CTCs of some malignant tumors, including CRC samples, by RT-PCR followed by southern blot hybridization. They reported no correlation between prognostic values of CTCs and clinical manifestations of CRC. 130 Histone-like protein (HLM), 120 tenascin C, 121 aquaporin (AQP5), 131 plakophilin 3, tyrosinase, prostate-specific antigen), 132 universal MAGE-A, 133 disheveled segment polarity protein 1 (DVL1), 134 CD47, 135 and 136 were proposed as markers in a smaller number of articles. The heterogeneity of CTC markers led some researchers to focus on multi-marker panels in data mining as listed in Table 4 . 101, 105, 109, 110, 114, 125, 129, [137] [138] [139] Exosomes Some prognosis markers have nearly the same functional patterns as molecular markers related to CRC. Studies have reported on colorectal exosome prognostic markers such as ALIX (ALG 2-interacting protein X), 140, 141 Hsp60, 142 Hsp70, 141 CEA, 143 ATP-binding cassette transporter G1 (ABCG1), 144 copine III (CPNE3), 145 and ΔNp73 70 in cancer patients. Tauro et al, used multiple isolation methods to detect known exosome markers such as ALIX, TSG101, HSP70, and other specific and novel markers listed in Table 5 . 141 Chen et al, applied bioinformatic analysis for introduction of two panels and validated them. 146 Chiba et al, reported that exosomes derived from CRC cell lines contain mRNA, microRNA, and natural antisense RNA as listed in Table 5 . 71 
Risk of bias (quality) assessment
All articles related to CTC (39 diagnosis-related and 57 prognosis-related) were assessed by NOS case-control guidelines as reported in Table S1 . Of the diagnosis-related articles (40% of the total), 43%, 43%, and 14% scored 7, 6, and 5, respectively. Of the prognosis-related articles (60% of the total), 49%, 31.5%, 14%, and 1.5% scored 7, 6, 5, and 4, respectively; and 4% could not to be scored.
All articles related to exosomes (Five diagnosis-related and nine prognosis-related) were assessed by the NOS casecontrol guidelines in Table S2 . Of the diagnosis-related articles (36% of total), 20%, 40%, and 40% scored 7, 6, and 5, respectively. Of the prognosis-related articles (64% of total), 67%, 22%, and 11% scored 7, 6, and 5, respectively. The 0-3 and 8-9 scores were not given out in these studies, so the NOS number varied from 4 to 7. About 99.3% of systematically imported articles scored over 5, 20% ofthe articless scored 5, and 79.7% scored 6 or 7.
Bioinformatics approach to systematic results
This systematic search identified 66 CTC gene markers for the diagnosis of CRC, 65 CTC gene markers for prognosis with repetition, 10 exosome gene markers for diagnosis of CRC, and 35 exosome gene markers for prognosis as shown in Tables 2-5 .
Protein-protein interaction network via STRING analysis
In the gene network, biochemical functions and identified pathways were obtained from gene expression data, and the results are shown in Figures 3 and 4 and supplementary Table S3 (online resources) . Surprisingly, the cellular components of exosomes and CTC highlight extracellular space, region and exosome, plasma membrane, and cell junction. Their molecular function highlights cell adhesion molecule binding and protein binding. Biological processes included regulation of cellular component movement, assembly, localization, organization, and response to external stimuli.
Gene ontology
The results of EnrichR web tools in supplementary Table S4 (online resources) can be used to accurately understand the molecular pathways. The common pathways in biomarkers such as proteoglycans in cancer, focal adhesion pathways in cancer, integrin, Rap1, MAPK signaling pathways, angiogenesis, p53 pathways, and viral processes were similar and related to cancer.
Discussion
CRC is a common malignancy that often has a poor prognosis. 147 The tumor microenvironment contributes to its progression 148 and cross-talk between cancer cells and exosomes play a critical role in this dynamic network. 149 Their identification and characterization are important steps to improve understanding of cellular and molecular cancer metastasis. Tracking of tumor-associated molecular markers in the blood can be used to assess the presence of residual disease, recurrence, and resistance. 150 This systematic review highlights new trends and approaches in CRC biomarker discovery using CTC and exosomes.
Evidence related to diagnosis of CRC by means of CTC markers was addressed in 38 articles ( exosomes, in addition to CD9, CD81, ALIX, and TSG101, were including EPCAM and HSP, especially using ultracentrifugation. Comparison of 131 CTC markers and 45 exosomes markers showed only three common markers (CEA, CD9, and EPCAM) on the gene list as diagnostic and prognostic biomarkers. A half-century-old investigation of CEA in CRC was the first step in the identification of a much larger family of 12 CEACAMs. 151, 152 Gene encoding CEA is a member of the immunoglobulin supergene family 153 that plays a role in cell adhesion and tumor progression, 154 even in protecting the colon from microbial infection. 155 CEA is involved in the metastatic cascade process through positive regulation of cell migration and invasion; [156] [157] [158] thus, the monitoring of CEA as a cost-effective and frequent indicator of recurrence of CRC has been investigated for years. 159 Integrin on tumor exosomes may play an important role in modulating organ-specific metastasis in cancer progression. CD9 is a member of the tetraspanin superfamily commonly detected in all types of exosomes involved in pathophysiologic processes such as cellular adhesion, growth, motility, cell-cell fusion, signal transduction, and tumor metastasis. 160 EPCAM is a membranous glycoprotein that is a CSC marker in tumor cells in the basolateral surface of most normal epithelial tissue and its role is to connect cells by means of calcium. The expression of this marker increases in benign and malignant tumors that arise from epithelial tissue. 161 The first step in metastasis is the separation of cancerous cells from primary tumors. CEA, CD9, and EPCAM are closely correlated with tumor progression as a poor prognostic factor and is required for the survival of CTCs in some cancers. 162 Taken together, it appears that the signature of the CTC and exosome biomarkers are similar and follow common pathways; thus, exosomes can be applied as alternative tools for guiding better molecular pathology in the fight against cancer.
Precision medicine is changing clinical practice by tailoring treatment based on an individual's genetic makeup. Recent studies have shown that CTC and circulating tumor DNA provide complementary information and the use of both approaches to study tumor metastasis is warranted. 163 CTC and exosomes can pave a path as diagnostic and prognostic procedures using the heterogeneity of tumor sites as they are released into the blood from live origins and can be 
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analyzed at the DNA, RNA, and protein levels. It is undeniable that more investigation is needed to compare them, especially for cancer patients. Various CTC isolating techniques each have its own advantages and disadvantages as to their CTC capture capacity and subgrouping of CTCs based on various markers. Similar problems also exist for exosomes, with a lack of a proven rapid and high-yield approach for extracting exosomes for downstream analysis. 164 Microfluidic devices and bioinformatics analysis might play an important role in solving the current shortcomings of the liquid biopsy concept. Microfluidics, by using inertial focusing/hydrodynamics (laminar flow in microchannels) and applying spiral, acoustic, electrophoretic, and electromagnetic features passively separate CTCs and exosomes from the other background calls. 165 Immobilizing specific antibodies either on micro-posts or in a herringbone design against their marker might be useful; it is easy to explore and yields quantitative readouts with high sensitivity, low cost, and minimal sample handling. Finally, although the potential clinical utility of these techniques is clear, more effort is needed to use the full potential of liquid biopsy in clinical settings. 166 
Future perspectives
Currently, isolation and purification of tumor-derived exosome in a worm bag of EVs is technically cumbersome and also isolation of CTCs has its own limitations. Therefore, combined use of these two biomarkers together as a liquid biopsy requires large-scale clinical trials. Microfluidic devices and bioinformatics analysis might play an important role in solving the current shortcomings of the liquid biopsy. Additionally, cross talking of CTCs and tumor-derived exosomes in a tumor microenvironment should become a heated question in exploring the premetastatic niche. As such, more research is needed on CTCs and exosome's overlapping molecular pathways to determine more effective biomarker signatures of CRC, especially in the metastatic form. 
Publish your work in this journal
Cancer Management and Research is an international, peer-reviewed open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient.
The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors. 
